Pediatric Hyperacute Arterial Ischemic Stroke Pathways at Canadian Tertiary Care Hospitals.


Journal

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
ISSN: 0317-1671
Titre abrégé: Can J Neurol Sci
Pays: England
ID NLM: 0415227

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 12 2 2021
medline: 7 4 2022
entrez: 11 2 2021
Statut: ppublish

Résumé

Childhood acute arterial ischemic stroke (AIS) is diagnosed at a median of 23 hours post-symptom onset, delaying treatment. Pediatric stroke pathways can expedite diagnosis. Our goal was to understand the similarities and differences between Canadian pediatric stroke protocols with the aim of optimizing AIS management. We contacted neurologists at all 16 Canadian pediatric hospitals regarding AIS management. Established protocols were analyzed for similarities and differences in eight domains. Response rate was 100%. Seven (44%) centers have an established AIS protocol and two (13%) have a protocol under development. Seven centers do not have a protocol; two redirect patients to adult neurology, five rely on a case-by-case approach for management. Analysis of the seven protocols revealed differences in: 1) IV-tPA dosage: age-dependent 0.75-0.9 mg/kg (N = 1) versus age-independent 0.9 mg/kg (N = 6), with maximum doses of 75 mg (N = 1) or 90 mg (N = 6); 2) IV-tPA lower age cut-off: 2 years (N = 5) versus 3 or 10 years (each N = 1); 3) IV-tPA exclusion criteria: PedNIHSS score <4 (N = 3), <5 (N = 1), <6 (N = 3); 4) first choice of pre-treatment neuroimaging: computed tomography (CT) (N = 3), magnetic resonance imaging (MRI) (N = 2) or either (N = 2); 5) intra-arterial tPA use (N = 3) and; 6) mechanical thrombectomy timeframe: <6 hour (N = 3), <24 hour (N = 2), unspecified (N = 2). Although 44% of Canadian pediatric hospitals have established AIS management pathways, several differences remain among centers. Some criteria (dosage, imaging) reflect adult AIS literature. Canadian expert consensus regarding IV-tPA and endovascular treatment should be established to standardize and implement AIS protocols across Canada.

Sections du résumé

BACKGROUND
Childhood acute arterial ischemic stroke (AIS) is diagnosed at a median of 23 hours post-symptom onset, delaying treatment. Pediatric stroke pathways can expedite diagnosis. Our goal was to understand the similarities and differences between Canadian pediatric stroke protocols with the aim of optimizing AIS management.
METHODS
We contacted neurologists at all 16 Canadian pediatric hospitals regarding AIS management. Established protocols were analyzed for similarities and differences in eight domains.
RESULTS
Response rate was 100%. Seven (44%) centers have an established AIS protocol and two (13%) have a protocol under development. Seven centers do not have a protocol; two redirect patients to adult neurology, five rely on a case-by-case approach for management. Analysis of the seven protocols revealed differences in: 1) IV-tPA dosage: age-dependent 0.75-0.9 mg/kg (N = 1) versus age-independent 0.9 mg/kg (N = 6), with maximum doses of 75 mg (N = 1) or 90 mg (N = 6); 2) IV-tPA lower age cut-off: 2 years (N = 5) versus 3 or 10 years (each N = 1); 3) IV-tPA exclusion criteria: PedNIHSS score <4 (N = 3), <5 (N = 1), <6 (N = 3); 4) first choice of pre-treatment neuroimaging: computed tomography (CT) (N = 3), magnetic resonance imaging (MRI) (N = 2) or either (N = 2); 5) intra-arterial tPA use (N = 3) and; 6) mechanical thrombectomy timeframe: <6 hour (N = 3), <24 hour (N = 2), unspecified (N = 2).
CONCLUSIONS
Although 44% of Canadian pediatric hospitals have established AIS management pathways, several differences remain among centers. Some criteria (dosage, imaging) reflect adult AIS literature. Canadian expert consensus regarding IV-tPA and endovascular treatment should be established to standardize and implement AIS protocols across Canada.

Identifiants

pubmed: 33568245
pii: S0317167121000275
doi: 10.1017/cjn.2021.27
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-838

Auteurs

Maria Gladkikh (M)

University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.

Hugh J McMillan (HJ)

University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.

Andrea Andrade (A)

London Children's Hospital, University of Western Ontario, Ottawa, ON, Canada.

Cyrus Boelman (C)

British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

Ishvinder Bhathal (I)

The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Janette Mailo (J)

Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.

Aleksandra Mineyko (A)

Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.

Mahendranath Moharir (M)

The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Sébastien Perreault (S)

Centre Hospitalier Sainte-Justine, University of Montreal, Montreal, QC, Canada.

Jonathan Smith (J)

Vancouver General Hospital, Vancouver Stroke Program, University of British Columbia, Vancouver, BC, Canada.

Daniela Pohl (D)

University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH